The Genitourinary Cancer Clinical Program provides compassionate, multidisciplinary care that is informed by research to develop the most effective therapies for urologic malignancies. Penn physicians conduct clinical research and other investigations to improve the ability to diagnose and treat patients with all types of genitourinary malignancies including bladder, prostate, renal, and testicular cancers. It is through such research that clinicians improve current treatment and develop future cancer treatments and care.
Penn’s Urological Cancer Program has a comprehensive team sub-specialist medical oncologists, urologists, radiation oncologist, pathologists, radiologists, nurse practitioners, and oncology nurse navigators. This group meets weekly to discuss treatment plans for patients, resulting in advanced and personalized treatment plans for each patient.
Penn physicians conduct a variety of ongoing clinical research studies, usually in close collaboration with other departments and divisions, including radiation oncology and urology.
These studies include:
- Assessment of new therapies for all stages of disease, including studies combining surgery, radiation and chemotherapy and immunotherapy.
- Assessment of new experimental agents for the treatment of patients with genitourinary cancer, including phase 1 clinical trials.
- Quality-of-life studies.
- Analysis of tissue, blood, and tumor samples to better understand the biology of the malignancies and relationship to patient outcomes (for example, our testicular cancer genetic susceptibility study).
Medical oncologists involved in the management of genitourinary cancer include: